Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Debt: 2012-2024

Historic Non-Current Debt for Adma Biologics (ADMA) over the last 10 years, with Dec 2024 value amounting to $72.3 million.

  • Adma Biologics' Non-Current Debt fell 30.83% to $70.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.1 million, marking a year-over-year decrease of 30.83%. This contributed to the annual value of $72.3 million for FY2024, which is 44.61% down from last year.
  • Latest data reveals that Adma Biologics reported Non-Current Debt of $72.3 million as of FY2024, which was down 44.61% from $130.6 million recorded in FY2023.
  • Over the past 5 years, Adma Biologics' Non-Current Debt peaked at $142.8 million during FY2022, and registered a low of $72.3 million during FY2024.
  • In the last 3 years, Adma Biologics' Non-Current Debt had a median value of $130.6 million in 2023 and averaged $115.3 million.
  • In the last 5 years, Adma Biologics' Non-Current Debt skyrocketed by 50.56% in 2022 and then crashed by 44.61% in 2024.
  • Yearly analysis of 5 years shows Adma Biologics' Non-Current Debt stood at $93.0 million in 2020, then grew by 2.04% to $94.9 million in 2021, then surged by 50.56% to $142.8 million in 2022, then decreased by 8.57% to $130.6 million in 2023, then crashed by 44.61% to $72.3 million in 2024.